Application of equisetin to preparation of osteoclast differentiation inhibitor

Abstract

The invention discloses application of equisetin to preparation of an osteoclast differentiation inhibitor. The equisetin disclosed by the invention can effectively inhibit osteoclast generation and differentiation, can exert an inhibition effect only when the concentration is 0.1 [mu]M, does not influence cell survival when the concentration is 4 [mu]M or less, and does not generate cytotoxicity,so that the equisetin can effectively replace an existing diphosphate drug and denosumab, the area of bone depression formed by the osteoclast in the sclerite is reduced, the bone resorption activityof the osteoclast is inhibited, and meanwhile, the expression of NF-kappaB and NFATc1 is down-regulated; and the equisetin has extremely high application value.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to the application of iquamycin in the preparation of osteoclast differentiation inhibitors. Background technique [0002] Osteoclasts (OCs) are the only cells capable of bone resorption in the human body. Osteoclasts originate from bone marrow mononuclear-macrophage lineage cells and are giant multinucleated cells formed by fusion of mononuclear precursor cells in various ways. Excessive activation of osteoclasts is not only common in menopausal osteoporosis, but also in bone destructive diseases such as bone loss caused by inflammatory diseases (such as bacterial infection), rheumatoid arthritis, and tumor bone metastasis. Therefore, drugs that target osteoclasts and inhibit osteoclast formation or function can only become an important means for the prevention and treatment of related bone destructive diseases. [0003] Currently, the clinically applicable ...

AI Technical Summary

Problems solved by technology

Although these two types of drugs can inhibit the differentiation or function of osteoclasts, they both have serious complications and unbearable side effects for patients

For example, taking bisphosphonates for a long time will inhibit the natural renewal of bone tissue, which will easily cause fractures; while denosimab needs subcutaneous injection, which is expensive. The most important thing is that long-term use of denosimab can cause mandibular necrosis other serious complications

Images